AlzeCure Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	97.33	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-
Gross Profit	97.33	-	-	-	-	-
Selling, General & Admin	13.02	11.88	11.47	10.6	10.17	11.27
Research & Development	60.47	37.49	24.8	27.71	46.18	66.72
Other Operating Expenses	-6.41	-1.4	-0.28	0.04	0.22	0.16
Operating Expenses	67.08	47.97	35.99	38.34	56.57	78.14
Operating Income	30.25	-47.97	-35.99	-38.34	-56.57	-78.14
Interest Expense	-0.24	-0.27	-0.35	-0.01	-0	-0
Interest & Investment Income	0.51	0.49	0.93	1.1	0.21	0.15
Currency Exchange Gain (Loss)	0.19	0.08	0.03	0.08	0.13	0.22
Pretax Income	30.71	-47.67	-35.38	-37.17	-56.24	-77.78
Income Tax Expense	-0.01	-0.02	-0.03	-	-	-
Net Income	30.72	-47.65	-35.35	-37.17	-56.24	-77.78
Net Income to Common	30.72	-47.65	-35.35	-37.17	-56.24	-77.78
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	114	100	77	62	48	38
Shares Outstanding (Diluted)	114	100	77	62	48	38
Shares Change	28.89%	30.26%	24.26%	30.17%	26.30%	-
EPS (Basic)	0.27	-0.47	-0.46	-0.60	-1.18	-2.06
EPS (Diluted)	0.27	-0.47	-0.46	-0.60	-1.18	-2.06
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-52.48	-34.59	-34.35	3.06	-99.91	-70.69
Free Cash Flow Per Share	-0.46	-0.34	-0.45	0.05	-2.10	-1.87
Gross Margin	100.00%	-	-	-	-	-
Operating Margin	31.08%	-	-	-	-	-
Profit Margin	31.56%	-	-	-	-	-
Free Cash Flow Margin	-53.92%	-	-	-	-	-
EBITDA	31.47	-46.7	-35	-37.87	-56	-77.57
D&A For EBITDA	1.22	1.27	1	0.48	0.57	0.58
EBIT	30.25	-47.97	-35.99	-38.34	-56.57	-78.14